BioPharmSignal logoBioPharmSignal

Biotech News

Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split

Jaguar Health (JAGX)Jaguar HealthCompany update

Reverse split approved at April 2026 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on April 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / April 27, 2026 / Jaguar Health, Inc. ( Nasdaq:JAGX) ("Jaguar" or the "Company") today announced

Open original release

Related news

JAGXJaguar Health2026-05-08 13:00 EST

Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule

JAGXJaguar Health2026-05-27 13:00 EST

Jaguar Health Compliant with Nasdaq Bid Price Rule

SCYXSCYNEXIS2025-12-22 13:00 EST

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

SCYXSCYNEXIS2026-05-22 20:15 EST

SCYNEXIS Announces One-for-Eight Reverse Stock Split

IBRXImmunityBio2026-04-06 11:30 EST

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

View all latest news

Jaguar Health

Jaguar Health is a biopharmaceutical company focused on gastrointestinal and rare-disease therapies, with Mytesi as a key commercial asset. Its story combines niche commercialization with a pipeline aimed at high-unmet-need GI indications.

Recent company news

JAGXJaguar Health2026-05-28 14:00 EST

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders

JAGXJaguar Health2026-05-27 13:00 EST

Jaguar Health Compliant with Nasdaq Bid Price Rule

JAGXJaguar Health2026-05-20 20:40 EST

Jaguar Health Reports First Quarter 2026 Financials

JAGXJaguar Health2026-05-20 13:00 EST

Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference

JAGXJaguar Health2026-05-19 13:00 EST

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer

Stock data

Close
1.00 USD
Market cap
2.12M USD
Exchange
NASDAQ
Sector
Biopharma
Location
San Francisco, California